Viroclinics Biosciences
Business Services · Netherlands · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Marconistraat 16, Rotterdam, South Holla...Phone Number
+31 886684787Website
www.viroclinics.comRevenue
$19.4 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Viroclinics Biosciences
VIROCLINICS-DDL is a global leading specialty contract research organization, serving the biopharmaceutical community with a broad range of preclinical research, clinical diagnostic, assay development and clinical trial logistic services. A global reach is offered to the company's clients through a network of 35 processing laboratories. VIROCLINICS-DDL's extensive experience with clinical and preclinical studies for viruses, including its specialty in respiratory and blood borne viruses, puts the company at the forefront in supporting the development of vaccines, antibodies and antiviral compounds targeting viral infectious diseases. The company's in-house state of the art preclinical and clinical BSL-2 and BSL-3 laboratories allow for complex experiments with highly pathogenic organisms. VIROCLINICS-DDL is based in Rotterdam, Rijswijk, Schaijk, (The Netherlands) and employs more than 300 well-trained, dedicated scientists and technical experts.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Viroclinics Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Viroclinics Biosciences has new funding data
Click to see if Viroclinics Biosciences had a recent Job posting/layoffs
Check if Viroclinics Biosciences has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Viroclinics Biosciences recently announced quarterly report
Product Launch: Get notified when Viroclinics Biosciences launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Viroclinics Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Viroclinics Biosciences
Check out if Viroclinics Biosciences is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Viroclinics Biosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Viroclinics Biosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Viroclinics Biosciences.
Viroclinics Biosciences Tech Stack
A closer look at the technologies used by Viroclinics Biosciences
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Left Company
Executive Move
Left Company
New Hire
Executive Move
New Hire
New Hire
Executive Move
Left Company
Executive Move
Viroclinics Biosciences News & Media
Cerba Healthcare Enters Agreement to Acquire Viroclinics-DDL Expanding and Transforming Its Offering in Clinical Trials
ISSY LES MOULINEAUX, France & ROTTERDAM, The Netherlands--(BUSINESS WIRE)--Cerba HealthCare, a leading global player in medical diagnosis, today announced it has reached agreement to acquire Viroclinics-DDL, a fast-growing global virology and immunology contract research organization (CRO) from Summit Partners. Viroclinics-DDL, employing a total of over 390 scientists and experts, offers a broad range of virology related services in the field of non-clinical and clinical trials, clinical diagnoAllarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus
Current positive results with delta variant B.1.617.2 follows previous pre-clinical tests, including testing of alpha variant B.1.1.7 (“British” variant), beta variant B.1351 (“South African” variant), and gamma variant P.1 (“Brazilian” variant).Caprion-HistoGeneX and Viroclinics-DDL announce a strategic partnership to offer integrated, complementary services to advance infectious disease research and COVID-19 therapeutic development
Caprion-HistoGeneX, a specialized CRO providing immunology, proteomics, histopathology and genomics services, and Viroclinics-DDL, a provider of preclinical and clinical trial services for vaccine, antiviral, and diagnostic development, are pleased to announce a new partnership that will...Davide Molho, DVM Joins Viroclinics Biosciences as Chief Executive Officer
ROTTERDAM, Netherlands, July 20, 2020 /PRNewswire/ -- Viroclinics Biosciences B.V. ("Viroclinics") today announced the appointment of life sciences industry veteran Davide Molho, DVM as the company's new Chief Executive Officer. Dr. Molho succeeds Bob van Gemen, PhD who has served as the...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Viroclinics Biosciences
Sign Up For FreeTo access detailed company insights
VIROCLINICS-DDL is a global leading specialty contract research organization, serving the biopharmaceutical community with a broad range of preclinical research, clinical diagnostic, assay development and clinical trial logistic services. A global reach is offered to the company's clients through a network of 35 processing laboratories. VIROCLINICS... Read More
